Journal: Nature Communications
Article Title: Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex
Figure Lengend Snippet: DC-34 silencs MYC expression in cancer cells. a Inhibition of L363 MM cell proliferation at 24 (IC 50 = 3.4 µM) (red), 48 (IC 50 = 3.4 µM) (green) and 72 h (IC 50 = 3.1 µM) (blue). b Inhibition of MYC protein translation with 5 μM of DC-34 is sustained over time in L363 cells. c The half maximal inhibitory concentration (IC 50 ) of DC-34 with respect to MYC protein inhibition as determined by Peggy protein expression. d A Western blot of MYC protein during a representative cycloheximide-chase degradation experiment with L363 multiple myeloma cells. Cells were treated with 10 µg/mL of cycloheximide (CX) in the absence or presence of DC-34 (5 µM) and MYC protein expression was assessed at indicated time points. β-actin was used as loading control. e MYC protein levels are inhibited as a function of the dose of DC-34 in L363 cells; only the highest dose of DC-34 affected MYC in the more resistant CA46 Burkitt’s lymphoma cells. f Western blot analysis of 293T cells transiently transfected with either GFP or CMV-MYC plasmid (the CMV promoter lacks a MYC G4) (right) and dosed with different concentrations of DC-34. All western blots were exposed for
Article Snippet: Proteins were separated by SDS-PAGE and analyzed by immunoblotting with c-myc (ab32072) and β-actin (cell signaling #4967) primary antibodies.
Techniques: Expressing, Inhibition, Concentration Assay, Western Blot, Transfection, Plasmid Preparation